IRIS
CARLOMAGNO, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.188
NA - Nord America 3.751
EU - Europa 3.078
SA - Sud America 521
Continente sconosciuto - Info sul continente non disponibili 173
AF - Africa 94
OC - Oceania 5
Totale 11.810
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.575
SG - Singapore 1.850
RU - Federazione Russa 1.220
IT - Italia 836
VN - Vietnam 822
CN - Cina 705
BR - Brasile 414
HK - Hong Kong 322
DE - Germania 206
FR - Francia 162
UA - Ucraina 145
FI - Finlandia 143
BD - Bangladesh 136
CA - Canada 117
IE - Irlanda 95
GB - Regno Unito 92
IN - India 90
JP - Giappone 59
NL - Olanda 58
AR - Argentina 40
IQ - Iraq 35
SE - Svezia 31
PH - Filippine 30
MX - Messico 28
ZA - Sudafrica 26
PL - Polonia 24
CI - Costa d'Avorio 22
KR - Corea 18
ES - Italia 17
TH - Thailandia 17
CO - Colombia 16
EC - Ecuador 13
TR - Turchia 13
PK - Pakistan 12
VE - Venezuela 12
AT - Austria 11
ID - Indonesia 11
LT - Lituania 10
JM - Giamaica 9
AZ - Azerbaigian 8
MA - Marocco 8
TW - Taiwan 8
CL - Cile 7
PY - Paraguay 7
GE - Georgia 6
KE - Kenya 6
MY - Malesia 6
NP - Nepal 6
UZ - Uzbekistan 6
AU - Australia 5
TN - Tunisia 5
UY - Uruguay 5
AL - Albania 4
BO - Bolivia 4
HN - Honduras 4
OM - Oman 4
CR - Costa Rica 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
EG - Egitto 3
HR - Croazia 3
IL - Israele 3
LY - Libia 3
PA - Panama 3
AE - Emirati Arabi Uniti 2
BA - Bosnia-Erzegovina 2
BE - Belgio 2
BY - Bielorussia 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
EU - Europa 2
GR - Grecia 2
GT - Guatemala 2
JO - Giordania 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LU - Lussemburgo 2
NG - Nigeria 2
PE - Perù 2
QA - Qatar 2
RO - Romania 2
SA - Arabia Saudita 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AD - Andorra 1
AO - Angola 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BJ - Benin 1
CV - Capo Verde 1
DK - Danimarca 1
GA - Gabon 1
GD - Grenada 1
GN - Guinea 1
GP - Guadalupe 1
GY - Guiana 1
IR - Iran 1
Totale 11.623
Salva come PNG Salva come JPEG
Città #
Singapore 778
San Jose 603
Moscow 313
Hong Kong 304
Ashburn 262
Naples 252
Ho Chi Minh City 241
Chandler 237
Beijing 209
Hanoi 196
Jacksonville 148
Santa Clara 134
The Dalles 118
Lauterbourg 107
Los Angeles 101
Millbury 100
Princeton 98
Napoli 79
Munich 68
Buffalo 66
Nanjing 66
New York 56
Boston 54
Ottawa 53
Wilmington 51
Hefei 47
Tokyo 47
Amsterdam 45
São Paulo 45
Dallas 41
Haiphong 34
Da Nang 32
Redondo Beach 31
Montreal 29
Nanchang 29
Woodbridge 26
Chicago 25
Orem 25
Helsinki 23
Brooklyn 22
Turku 22
Warsaw 21
Salerno 20
Atlanta 19
Augusta 19
Chennai 19
Des Moines 19
Rome 19
Milan 18
Shenyang 18
Frankfurt am Main 16
Mexico City 16
Seattle 16
Shanghai 16
Hebei 15
Hải Dương 15
Lawrence 15
Nocera Superiore 15
Poplar 15
Council Bluffs 14
Houston 14
London 14
Rio de Janeiro 14
Baghdad 13
Falls Church 13
Nuremberg 13
Boardman 12
Giugliano in Campania 12
Kronberg 12
Kunming 12
Ann Arbor 11
Changsha 11
Manchester 11
Ninh Bình 11
Thái Bình 11
Denver 10
Hangzhou 10
Phoenix 10
Tianjin 10
Toronto 10
Waldbuttelbrunn 10
Biên Hòa 9
Can Tho 9
Kochi 9
Mumbai 9
San Francisco 9
San Mateo 9
Washington 9
Brasília 8
Düsseldorf 8
Erbil 8
Guarulhos 8
Johannesburg 8
Nha Trang 8
Nola 8
Seoul 8
Stockholm 8
Thái Nguyên 8
Acerra 7
Belo Horizonte 7
Totale 5.943
Salva come PNG Salva come JPEG
Nome #
Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms 248
Mechanisms of RET mediated signal transduction 201
NCOA4 links iron bioavailability to DNA metabolism 185
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms 181
Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis 169
Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase 168
NCOA4 inhibits initiation of DNA replication to maintain genome stability 166
Therapeutic strategies to target the receptor tyrosine kinase AXL in thyroid cancer 160
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes 151
Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas 150
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology 149
The Insulin Receptor Substrate (IRS)-1 recruits Phosphatidylinositol 3-Kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. 145
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases 144
Ultrasound-induced mechanical damage of cancer cell cytoskeleton causes disruption of nuclear envelope and activation of cGAS-STING 143
NCOA4 Deficiency Impairs Systemic Iron Homeostasis 140
Molecular biology of the MEN2 gene 139
Bioisosteric discovery of npa101.3, a second-generation ret/vegfr2 inhibitor optimized for single-agent polypharmacology 138
Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease 136
I geni oncosoppressori in "Patologia Generale" IV Ed, Pontieri-Russo-Frati 134
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). 133
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases 132
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. 131
Different mutations of the RET gene cause different human tumoral diseases. 129
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. 129
NCOA4 Links Iron Bioavailability to DNA Metabolism 126
Molecular mechanisms of RET activation in human cancer 125
Ret gene fusions in malignancies of the thyroid and other tissues 125
BAY 43-9006 inhibition of oncogenic RET mutants 124
Ret-mediated mitogenesis requires Src kinase activity. 123
Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene. 122
Receptor- and non-receptor tyrosine kinases induce processing of the amyloid precursor protein: role of the low-density lipoprotein receptor-related protein. 120
NCOA4 transcriptional coactivator inhibits activation of DNA replication origins. 120
The extent of linkage disequilibrium in four populations with distinct demographic histories 115
The Macrophage Nuclear Receptor Coactivator 4 Counteracts Iron-Deficiency Anemia 114
Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation. 112
RET ONCOGENE ACTIVATION IN HUMAN THYROID NEOPLASMS IS RESTRICTED TO THE PAPILLARY CANCER SUBTYPE 111
Evolutionary conservation of the Eps8 gene and its mapping to human-chromosome 12q23-q24 111
Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer 109
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival 109
The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model 109
BRAF is a therapeutic target in aggressive thyroid carcinoma. 107
Constitutive and AP20187-induced ret activation in photoreceptors does not protect from light-induced damage 107
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose 107
Molecular heterogeneity of RET loss of function in Hirschsprung's disease 106
Tamoxifen erythroid toxicity revealed by studying the role of nuclear receptor co-activator 4 in erythropoiesis 106
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) 104
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer 104
NCOA4-mediated ferritinophagy in macrophages is crucial to sustain erythropoiesis in mice 104
Signalling of the Ret receptor tyrosine kinase through the c-Jun N-terminal Protein Kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret 103
Different mutations of the RET gene cause different human tumoral diseases. 101
Molecular heterogeneity of RET loss of function in Hirschsprung's disease. 100
Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. 100
Antitumor effects of ZD6474, a small molecule Vascular Endothelial Growth Factor receptor tyrosine kinase inhibitor, with additional activity against Epidermal Growth Factor. 99
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation 99
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma 98
Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism 98
Comparison of DNA repair protein expression and activities between human fibroblast cell lines with different radiosensitivities 97
Cloning of the rat tissue inhibitor of metalloproteinases type 2 (TIMP-2) gene: analysis of its expression in normal and transformed thyroid cells. 95
POR Campania FESR SATIN 94
Iron and ferritin modulate MHC Class i expression and NK cell recognition 94
RET\PTC activation in human thyroid carcinomas 93
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. 92
Benzimidazole Analogues and related methods 92
Activation of RET oncogene and thyroid carcinogenesis 90
Attacking cancer with molecularly targeted agents 90
Molecular mechanisms of RET activation in human neoplasia 89
Molecular mechanisms of RET activation in human cancer. 88
Ret-mediated mitogenesis requires Src kinase activity. 87
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. 86
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation 86
Molecular mechanisms of RET activation in human neoplasia. 85
Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. 84
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase 84
Activation of RET as a dominant transforming gene by germline mutatios of MEN2A and MEN2B 83
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas 82
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase 82
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affaected by familial medullary thyroid carcinoma. 81
Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. 81
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. 79
Oncogenic rearrangements driving ionizing radiation-associated human cancer 78
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. 77
Basi molecolari delle nuove terapie: inibitori delle protein-chinasi. 76
Molecular targeting of the RET kinase in thyroid cancer 76
Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. 76
Ret-mediated mitogenesis requires Src kinase activity 75
Central role of RET in thyroid cancer 75
Receptor tyrosine kinases as targets for anticancer therapeutics 73
POINT MUTATION OF THE RET PROTO-ONCOGENE IN THE TT HUMAN MEDULLARY THYROID CARCINOMA CELL LINE 72
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase. 71
Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A 69
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. 69
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application 69
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma 67
Receptor tyrosine kinase inhibitors in thyroid cancer. 67
Minireview:RET:normal and abnormal functions 67
Ret-mediated mitogenesis requires Src kinase activity. 67
Molecular Mechanism of RET in Human Cancer 65
Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells 65
Ret-mediated mitogenesis requires Src kinase activity 64
The Human Eps15 gene encoding a tyrosine kinase substrate is conserved in evolution and map to 1p31-1p32 63
Totale 10.714
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.025
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.025
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022600 9 3 17 3 5 20 25 31 103 36 119 229
2022/2023643 123 49 5 52 76 65 10 54 92 60 42 15
2023/2024568 22 93 62 48 44 53 22 54 16 8 110 36
2024/20252.917 162 218 25 25 58 144 355 198 215 307 910 300
2025/20265.696 714 369 536 529 907 220 686 292 730 390 159 164
2026/2027103 103 0 0 0 0 0 0 0 0 0 0 0
Totale 11.810